Application of koumine to preparation of drugs for treating hepatocyte damage
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of hepatocyte injury and glucosinolates, which is applied in the field of biomedicine and can solve the problems that there are no literature reports on the prevention and treatment effects of glucosinolates, no new use descriptions, etc.
Pending Publication Date: 2020-06-19
THE NAVAL MEDICAL UNIV OF PLA
View PDF2 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Chinese patent CN101323618B discloses a method for extracting and isolating kelkinin from kelvin plants, but does not explain its new use
At present, there is no literature report on the prevention and treatment of kinesin in diseases or diseases related to liver cell injury
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0036] Example 1: Protective effect of kinesin on human liver cell L02 cells exposed to aflatoxin
[0037] Aflatoxin (AFB1)-exposed cell model was made using normal human liver cells L02 cells:
[0038] (1) Use RPMI-1640 medium (90%) + FBS (10%) + double antibody (1%) to culture L02 cells, passage once every 2 to 3 days, and the culture environment is 37°C, containing 5% CO 2 Incubator, when the density reaches more than 80%, subculture is carried out, the subculture ratio is 1:2, and the cells between the 10th generation and the 40th generation are selected for the experiment;
[0039] (2) 5 mg AFB1 was fully dissolved in 250 μL dimethyl sulfoxide to a 20 mg / ml stock solution, and then diluted to a concentration of 10 μM with RPMI-1640 medium;
[0040] (3) Fully dissolve 2 mg of kelkinin with 100 μL dimethyl sulfoxide to a 20 mg / mL stock solution, and then dilute it to a concentration of 20 μM or 5 μM with RPMI-1640 medium;
[0041] (4) L02 cells were treated with 1×10 5 T...
Embodiment 2
[0045] Example 2 Kiskinin increases the expression level of growth-related genes in human liver L02
[0046] The method in Example 1 was used to make aflatoxin AFB1-exposed cell model. After 33 hours, the blank control group, the hooked kiss treatment group and the negative control group all discarded the culture medium, washed twice with 100 μL / well of PBS, removed the residual medium, added 50 μL TRIzol to each well, repeatedly blown and beat the cells to fully lyse, and collected them in In EP tube.
[0047] 1. RNA extraction:
[0048] A. Take an appropriate amount of cell samples, add 600 μL Lysis / Binding Buffer, and homogenate; add 30 μL miRNAHomogenateAdditive, mix well and ice-bath for 10 minutes; B. Add an equal volume of phenol or chloroform, centrifuge at the maximum speed for 5 minutes at room temperature, and take the supernatant; C. Add 1. 25 times the volume of 100% ethanol and add the mixture to the spin column (up to 700 μL), room temperature, 13000 rpm, 30 s...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to the technical field of medicine, provides an application of koumine or pharmaceutically acceptable salt of koumine to preparation of drugs for treating hepatocyte damage, andfurther provides pharmaceutically composition for treating the hepatocyte damage. The pharmaceutically composition comprises an active ingredient and pharmaceutically acceptable auxiliary materials, and the active ingredient is koumine or the pharmaceutically acceptable salt of koumine, or is composition of koumine or the pharmaceutically acceptable salt of koumine and one or more other active ingredients. A pharmacology experiment shows that lower-concentration koumine can improve normal and aflatoxin-exposed human liver L02 cell activity; and by transcriptomics analysis, koumine can improveexpression of liver cell growth related genes, so that the effect of promoting liver cell growth is realized, for example, koumine can remarkably improve transcriptional level of genes such as EGR3, CCN2 and CCN1 related to L02 cell division, proliferation and growth functions. Therefore, new theoretical foundation is provided for koumine or the salt of koumine in the aspect of hepatocyte damage treatment.
Description
technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of kinesin or a pharmaceutically acceptable salt thereof in the preparation of medicines for treating liver cell damage, and a pharmaceutical composition containing kelesin. Background technique [0002] The liver is not only the most important nutrient metabolism organ in the human body, but also the biotransformation organ of many non-nutrient substances such as drugs, poisons and toxic metabolites, so it is easily affected by various substances ingested into the body and cause damage. It is now known that there are a variety of liver pathogenic factors, such as virus, bacterial infection, chemical poisons, drug intake, immune dysfunction, and ischemia-reperfusion injury, etc., which can lead to liver cell damage and liver function damage, so that the liver cannot perform Normal function, and then lead to a series of symptoms, and even evolve into acute an...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more